Comparative Pharmacology
Head-to-head clinical analysis: GONITRO versus NITROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GONITRO versus NITROL.
GONITRO vs NITROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nitric oxide (NO) donor; activates guanylyl cyclase, increasing cGMP in vascular smooth muscle, leading to vasodilation.
NITROL (nitroglycerin) is a vasodilator that relaxes vascular smooth muscle via the release of nitric oxide (NO), which activates guanylate cyclase and increases cyclic guanosine monophosphate (cGMP) levels, leading to vasodilation.
Sublingual: 0.3-0.6 mg at onset of angina, may repeat every 5 minutes up to 3 doses within 15 minutes. Prophylactic: 0.3-0.6 mg 5-10 minutes before activity. Transdermal: Apply 0.2-0.8 mg/hour patch once daily, remove at bedtime to prevent tolerance. Intravenous: Start at 5 mcg/min, titrate by 5-20 mcg/min every 3-5 minutes based on hemodynamic response; usual range 10-200 mcg/min.
Sublingual: 0.3-0.6 mg every 5 minutes as needed for angina, up to 3 doses in 15 minutes. Translingual spray: 1-2 sprays (0.4 mg/spray) under tongue every 5 minutes as needed, max 3 doses in 15 minutes. Transdermal: 0.2-0.8 mg/hour patch applied daily for 12-14 hours. Intravenous: Initial 5 mcg/min, titrate by 5 mcg/min every 3-5 minutes until response, usual range 10-200 mcg/min.
None Documented
None Documented
Terminal elimination half-life approximately 2-3 minutes for nitroglycerin; clinical effects cease within 30-60 minutes due to rapid redistribution and metabolism
1-4 minutes for nitroglycerin; clinical effect disappears within 30-60 minutes due to rapid metabolism and redistribution.
Primarily renal: 80-90% as inactive metabolites (dinitrates, mononitrates); minor biliary/fecal (<10%)
Renal: minimal, <1% unchanged; extensive metabolism by liver, metabolites excreted renally. Biliary/fecal: negligible.
Category C
Category C
Nitrate Vasodilator
Nitrate Vasodilator